Charles Schwab
AKYA

Charles Schwab’s Akoya BioSciences AKYA Stock Holding History

Charles Schwab’s Portfolio AKYA Stock Details AKYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-63,026
Closed -$87.6K – 3498
2025
Q1 		$87.6K Buy
63,026
+24
+0% +$53 ﹤0.01% 3361
2024
Q4 		$144K Hold
63,002
– – ﹤0.01% 3365
2024
Q3 		$171K Sell
63,002
-112,886
-64% -$276K ﹤0.01% 3350
2024
Q2 		$412K Buy
175,888
+4,112
+2% +$13.1K ﹤0.01% 3272
2024
Q1 		$806K Sell
171,776
-33,073
-16% -$172K ﹤0.01% 2859
2023
Q4 		$1,000K Buy
204,849
+51,410
+34% +$214K ﹤0.01% 2832
2023
Q3 		$713K Buy
153,439
+23,132
+18% +$133K ﹤0.01% 2913
2023
Q2 		$963K Buy
130,307
+6,294
+5% +$42K ﹤0.01% 2785
2023
Q1 		$1.01M Sell
124,013
-1,203
-1% -$12.6K ﹤0.01% 2725
2022
Q4 		$1.2M Buy
125,216
+2,350
+2% +$28.9K ﹤0.01% 2722
2022
Q3 		$1.44M Buy
122,866
+53,335
+77% +$703K ﹤0.01% 2684
2022
Q2 		$894K Buy
69,531
+2,130
+3% +$22.1K ﹤0.01% 2836
2022
Q1 		$741K Buy
67,401
+7,243
+12% +$84K ﹤0.01% 2970
2021
Q4 		$922K Buy
60,158
+13,392
+29% +$175K ﹤0.01% 2946
2021
Q3 		$653K Sell
46,766
-3,756
-7% -$62.8K ﹤0.01% 3051
2021
Q2 		$978K Buy
+50,522
New +$1.04M ﹤0.01% 2942

Other funds holding AKYA

BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCA
Peddock Capital Advisors Braintree, Massachusetts $501M AUM 29.8% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Charles Schwab's AKYA Position: Q2 2025 in Review

Charles Schwab sold out of Akoya BioSciences (AKYA) in Q2 2025, closing a stake of 63,026 shares — an estimated $87.6K sold.

Charles Schwab first reported a position in AKYA in Q2 2021 and held it in 16 quarters. The position peaked at $1.44M in Q3 2022. 58 funds tracked by Wall St. Rank hold AKYA as of Q2 2025.

  • Charles Schwab reported no remaining Akoya BioSciences position as of Q2 2025 after selling out during the quarter.
  • Charles Schwab sold 63,026 Akoya BioSciences shares in Q2 2025, an estimated $87.6K.
  • Charles Schwab first reported a position in Akoya BioSciences in Q2 2021 and held it in 16 quarters.
  • Charles Schwab's Akoya BioSciences position peaked at $1.44M in Q3 2022.
  • 58 funds tracked by Wall St. Rank held Akoya BioSciences as of Q2 2025.

Based on Charles Schwab's 13F filing for Q2 2025, filed 12 Aug 2025.